Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 1/2016

01-01-2016 | Review

Neutrophilic dermatoses and autoinflammatory diseases with skin involvement—innate immune disorders

Authors: Alexander A. Navarini, Takashi K. Satoh, Lars E. French

Published in: Seminars in Immunopathology | Issue 1/2016

Login to get access

Abstract

Neutrophilic dermatoses (NDs) such as Sweet’s syndrome and pyoderma gangrenosum were first described more than 50 years ago and grouped based on their clinical features combined with the typical, neutrophil-rich cutaneous inflammation. In contrast, the recently identified autoinflammatory diseases (ADs) that are also associated with neutrophil granulocyte infiltration of the skin were first characterized based on their genetic architecture. Though both the older ND and the newer AD encompass distinct conditions, they can be seen as parts of a spectrum of innate inflammation. Both groups of diseases show so many overlapping clinical, pathogenetic, histologic, and genetic features that together they should likely be considered as innate immune disorders.
Literature
1.
2.
McDermott MF, Aksentijevich I, Galon J et al (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97:133–144PubMedCrossRef
3.
French FMFC (1997) A candidate gene for familial Mediterranean fever. Nat Genet 17:25–31CrossRef
4.
5.
de Jesus AA, Canna SW, Liu Y, Goldbach-Mansky R (2015) Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annu Rev Immunol 33:823–874PubMedPubMedCentralCrossRef
6.
Tanaka N, Izawa K, Saito MK et al (2011) High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an international multicenter collaborative study. Arthritis Rheum 63:3625–3632PubMedPubMedCentralCrossRef
7.
8.
Aksentijevich I, Masters SL, Ferguson PJ et al (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360:2426–2437PubMedPubMedCentralCrossRef
9.
de Koning HD, van Gijn ME, Stoffels M et al (2015) Myeloid lineage-restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. J Allergy Clin Immunol 135:561–564PubMedCrossRef
10.
11.
Kastner DL (1998) Familial Mediterranean fever: the genetics of inflammation. Hospital practice 33:31–34, 9–40, 43–6 passimCrossRef
12.
Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 27:621–668PubMedPubMedCentralCrossRef
13.
Kitamura A, Sasaki Y, Abe T, Kano H, Yasutomo K (2014) An inherited mutation in NLRC4 causes autoinflammation in human and mice. J Exp Med 211:2385–2396PubMedPubMedCentralCrossRef
14.
Drenth JP, Cuisset L, Grateau G et al (1999) Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group Nat Genet 22:178–181
15.
Simon A, Bijzet J, Voorbij HA, Mantovani A, van der Meer JW, Drenth JP (2004) Effect of inflammatory attacks in the classical type hyper-IgD syndrome on immunoglobulin D, cholesterol and parameters of the acute phase response. J Intern Med 256:247–253PubMedCrossRef
16.
Kuijk LM, Beekman JM, Koster J, Waterham HR, Frenkel J, Coffer PJ (2008) HMG-CoA reductase inhibition induces IL-1beta release through Rac1/PI3K/PKB-dependent caspase-1 activation. Blood 112:3563–3573PubMedCrossRef
17.
Stojanov S, Dejaco C, Lohse P et al (2007) Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann Rheum Dis 67:1292–1298CrossRef
18.
Majeed HA, Kalaawi M, Mohanty D et al (1989) Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis in three related children and the association with Sweet syndrome in two siblings. J Pediatr 115:730–734PubMedCrossRef
19.
Jesus AA, Osman M, Silva CA et al (2011) A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Arthritis & Rheum 63:4007–4017CrossRef
20.
21.
Ramantani G, Kohlhase J, Hertzberg C et al (2010) Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutières syndrome. Arthritis & Rheum 62:1469–1477CrossRef
22.
Kitamura A, Maekawa Y, Uehara H et al (2011) A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J Clin Invest 121:4150–4160PubMedPubMedCentralCrossRef
23.
Lausch E, Janecke A, Bros M et al (2011) Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity. Nat Genet 43:132–137PubMedCrossRef
24.
Briggs TA, Rice GI, Daly S et al (2011) Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet 43:127–131PubMedCrossRef
25.
Kanazawa N (2004) Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor- B activation: common genetic etiology with Blau syndrome. Blood 105:1195–1197PubMedCrossRef
26.
Jordan Catherine T, Cao L, Roberson Elisha DO et al (2012) Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Ame J Hum Gen 90:796–808CrossRef
27.
Rigaud S, Fondanèche M-C, Lambert N et al (2006) XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444:110–114PubMedCrossRef
28.
Speckmann C, Lehmberg K, Albert MH et al (2013) X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis. Clin Immunol 149:133–141PubMedCrossRef
29.
Lindor NM, Arsenault TM, Solomon H, Seidman CE, McEvoy MT (1997) A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 72:611–615PubMedCrossRef
30.
Wise CA, Gillum JD, Seidman CE et al (2002) Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 11:961–969PubMedCrossRef
31.
Dierselhuis MP, Frenkel J, Wulffraat NM, Boelens JJ (2005) Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford) 44:406–408CrossRef
32.
Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P (2009) Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 161:1199–1201PubMedCrossRef
33.
Alecu M, Coman G, Musetescu A, Cojoaca ME, Coman OA (2015) Dermatology facing autoinflammatory syndrome. Rev Roum de Morpho et embryol 56:7–14
34.
Marzano AV, Ishak RS, Saibeni S, Crosti C, Meroni PL, Cugno M (2013) Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet’s syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol 45:202–210PubMedCrossRef
35.
36.
37.
Chakraborty PK, Schmitz-Abe K, Kennedy EK et al (2014) Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood 124:2867–2871PubMedPubMedCentralCrossRef
38.
Wiseman DH, May A, Jolles S et al (2013) A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Blood 122:112–123PubMedPubMedCentralCrossRef
39.
Onoufriadis A, Simpson Michael A, Pink Andrew E et al (2011) Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 89:432–437PubMedPubMedCentralCrossRef
40.
Marrakchi S, Guigue P, Renshaw BR et al (2011) Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. New England Journal of Medicine 365:620–628PubMedCrossRef
41.
Setta-Kaffetzi N, Simpson Michael A, Navarini Alexander A et al (2014) AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am J Hum Genet 94:790–797PubMedPubMedCentralCrossRef
42.
Sibley CH, Plass N, Snow J et al (2012) Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis & Rheumatism 64:2375–2386CrossRef
43.
Zhou Q, Lee G-S, Brady J et al (2012) A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am J Hum Genet 91:713–720PubMedPubMedCentralCrossRef
44.
Ueki Y, Lin C-Y, Senoo M et al (2007) Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 “cherubism” mice. Cell 128:71–83PubMedCrossRef
45.
Wallach D (1991) Les dermatoses neutrophiliques. (Editorial). Presse Med 20:105–107PubMed
46.
47.
Jo T, Horio K, Migita K (2015) Sweet’s syndrome in patients with MDS and MEFV mutations. N Engl J Med 372:686–688PubMedCrossRef
48.
Miyoshi T, Yamashita K, Ohno T et al (2008) Familial Mediterranean fever gene as a possible modifier of Sweet syndrome with chronic myelogenous leukemia. Acta Haematol 120:57–62PubMedCrossRef
49.
Imhof L, Meier B, Frei P et al (2015) Severe Sweet’s syndrome with elevated cutaneous interleukin-1beta after azathioprine exposure: case report and review of the literature. Dermatology 230:293–298PubMedCrossRef
50.
Brunsting LA, Goeckerman WH, O’Leary PA (1930) Pyoderma (echthyma) gangrenosum: clinical and experimental observations in five cases occurring in adults. Arch Derm Syphilol 22:655–680CrossRef
51.
Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB, White WL, Callen JP (2000) Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 79:37–46CrossRef
52.
Kolios AG, Maul JT, Meier B, Kerl K, Traidl-Hoffmann C, Hertl M, Zillikens D, Röcken M, Ring J, Facchiano A, Mondino C, Yawalkar N, Contassot E, Navarini AA, French LE (2015) Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol. doi:10.​1111/​bjd.​14037
53.
Caughman W, Stern R, Haynes H (1983) Neutrophilic dermatosis of myeloproliferative disorders. Atypical forms of pyoderma gangrenosum and Sweet’s syndrome associated with myeloproliferative disorders. J Am Acad Dermatol 9:751–758PubMedCrossRef
54.
Prat L, Bouaziz JD, Wallach D, Vignon-Pennamen MD, Bagot M (2014) Neutrophilic dermatoses as systemic diseases. Clin Dermatol 32:376–388PubMedCrossRef
55.
Ahmad K, Ramsay B (2009) Pyoderma gangrenosum associated with subcorneal pustular dermatosis and IgA myeloma. Clin Exp Dermatol 34:46–48PubMedCrossRef
56.
Hansen U, Haerslev T, Knudsen B, Jacobsen GK (1994) Erythema elevatum diutinum: case report showing an unusual distribution. Cutis 53:124–126PubMed
57.
Chimenti S, Ackerman AB (1981) Is subcorneal pustular dermatosis of Sneddon and Wilkinson an entity sui generis? Am J Dermatopathol 3:363–376PubMedCrossRef
58.
Anzalone CL, Cohen PR (2013) Acute febrile neutrophilic dermatosis (Sweet’s syndrome). Curr Opin Hematol 20:26–35PubMedCrossRef
59.
Yasukawa K, Kato N, Aikawa K, Kodama K, Hamasaka A, Hata H (2007) Neutrophilic eccrine hidradenitis with sclerodermoid change heralding the relapse of acute myelogenous leukemia: is this a paraneoplastic phenomenon? Dermatology 215:261–264PubMedCrossRef
60.
Rochet NM, Chavan RN, Cappel MA, Wada DA, Gibson LE (2013) Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients. J Am Acad Dermatol 69:557–564PubMedCrossRef
61.
Larson AR, Granter SR (2014) Systemic lupus erythematosus-associated neutrophilic dermatosis—an underrecognized neutrophilic dermatosis in patients with systemic lupus erythematosus. Hum Pathol 45:598–605PubMedCrossRef
62.
Marzano AV, Capsoni F, Berti E, Gasparini G, Bottelli S, Caputo R (1996) Amicrobial pustular dermatosis of cutaneous folds associated with autoimmune disorders: a new entity? Dermatology 193:88–93PubMedCrossRef
63.
Llamas-Velasco M, García-Martín P, Sánchez-Pérez J, Fraga J, García-Diez A (2013) Sweet’s syndrome with subcutaneous involvement associated with pegfilgrastim treatment: first reported case. J Cutan Pathol 40:46–49PubMedCrossRef
64.
Grelle JL, Halloush RA, Khasawneh FA. Azathioprine-induced acute febrile neutrophilic dermatosis (Sweet’s syndrome). BMJ Case Rep 2013;2013
65.
Momen SE, Jorizzo J, Al-Niaimi F (2014) Erythema elevatum diutinum: a review of presentation and treatment. J Eur Acad Dermatol Venereol 28:1594–1602PubMedCrossRef
66.
Park CW, Kim YJ, Seo HJ et al (2012) A case of Sweet’s syndrome in a patient with liver cirrhosis caused by chronic hepatitis B. Korean J Gastroenterol 59:441–444PubMedCrossRef
67.
Marzano AV, Cugno M, Trevisan V et al (2010) Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol 162:100–107PubMedPubMedCentralCrossRef
68.
Marzano AV, Fanoni D, Antiga E et al (2014) Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin Exp Immunol 178:48–56PubMedPubMedCentralCrossRef
69.
Giasuddin AS, El-Orfi AH, Ziu MM, El-Barnawi NY (1998) Sweet’s syndrome: is the pathogenesis mediated by helper T cell type 1 cytokines? J Am Acad Dermatol 39:940–943PubMedCrossRef
70.
Amazan E, Ezzedine K, Mossalayi MD, Taieb A, Boniface K, Seneschal J (2014) Expression of interleukin-1 alpha in amicrobial pustulosis of the skin folds with complete response to anakinra. J Am Acad Dermatol 71:e53–e56PubMedCrossRef
71.
Amano Y, Lee SW, Allison AC (1993) Inhibition by glucocorticoids of the formation of interleukin-1 alpha, interleukin-1 beta, and interleukin-6: mediation by decreased mRNA stability. Mol Pharmacol 43:176–182PubMed
72.
Lundberg I, Kratz AK, Alexanderson H, Patarroyo M (2000) Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 43:336–348PubMedCrossRef
73.
Acquitter M, Plantin P, Kupfer I, Auvinet H, Marhadour T (2015) Anakinra improves pyoderma gangrenosum in psoriatic arthritis: a case report. Ann Intern Med 163:70–71PubMedCrossRef
74.
Torrelo A, Patel S, Colmenero I et al (2010) Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. J Am Acad Dermatol 62:489–495PubMedCrossRef
75.
Liu Y, Ramot Y, Torrelo A et al (2012) Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 64:895–907PubMedPubMedCentralCrossRef
76.
Aksentijevich I, Masters SL, Ferguson PJ et al (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360:2426–2437PubMedPubMedCentralCrossRef
77.
Oskay T, Anadolu R (2009) Sweet’s syndrome in familial Mediterranean fever: possible continuum of the neutrophilic reaction as a new cutaneous feature of FMF. J Cutan Pathol 36:901–905PubMedCrossRef
78.
Nesterovitch AB, Gyorfy Z, Hoffman MD et al (2011) Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6/SHP1) may contribute to neutrophilic dermatoses. Am J Pathol 178:1434–1441PubMedPubMedCentralCrossRef
79.
DeFilippis EM, Feldman SR, Huang WW (2015) The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. Br J Dermatol 172:1487–1497PubMedCrossRef
Metadata
Title
Neutrophilic dermatoses and autoinflammatory diseases with skin involvement—innate immune disorders
Authors
Alexander A. Navarini
Takashi K. Satoh
Lars E. French
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 1/2016
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-015-0549-6

Other articles of this Issue 1/2016

Seminars in Immunopathology 1/2016 Go to the issue

Review

Adverse cutaneous drug eruptions: current understanding

Review

Cutaneous dermatomyositis in the era of biologicals

Review

Cutaneous immunology: basics and new concepts

Review

Immune response in pemphigus and beyond: progresses and emerging concepts

Review

The role of innate immune signaling in the pathogenesis of atopic dermatitis and consequences for treatments

Introduction

The skin and its blossoms—fertile soil for clinical science
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits